nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP2C19—Rosuvastatin—atherosclerosis	0.0601	0.0886	CbGbCtD
Etravirine—CYP2C19—Simvastatin—atherosclerosis	0.0559	0.0824	CbGbCtD
Etravirine—CYP2C19—Lovastatin—atherosclerosis	0.0547	0.0806	CbGbCtD
Etravirine—CYP2C9—Rosuvastatin—atherosclerosis	0.05	0.0737	CbGbCtD
Etravirine—ABCB1—Ezetimibe—atherosclerosis	0.0485	0.0715	CbGbCtD
Etravirine—CYP2C9—Simvastatin—atherosclerosis	0.0465	0.0685	CbGbCtD
Etravirine—CYP2C9—Pravastatin—atherosclerosis	0.0455	0.0671	CbGbCtD
Etravirine—CYP2C9—Lovastatin—atherosclerosis	0.0455	0.0671	CbGbCtD
Etravirine—ABCB1—Simvastatin—atherosclerosis	0.0451	0.0665	CbGbCtD
Etravirine—ABCB1—Pravastatin—atherosclerosis	0.0441	0.0651	CbGbCtD
Etravirine—ABCB1—Lovastatin—atherosclerosis	0.0441	0.0651	CbGbCtD
Etravirine—CYP3A4—Rosuvastatin—atherosclerosis	0.0291	0.0429	CbGbCtD
Etravirine—CYP3A4—Ezetimibe—atherosclerosis	0.0291	0.0429	CbGbCtD
Etravirine—CYP3A4—Simvastatin—atherosclerosis	0.027	0.0398	CbGbCtD
Etravirine—CYP3A4—Lovastatin—atherosclerosis	0.0264	0.039	CbGbCtD
Etravirine—CYP3A4—Pravastatin—atherosclerosis	0.0264	0.039	CbGbCtD
Etravirine—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.000994	0.00477	CcSEcCtD
Etravirine—Amnesia—Pravastatin—atherosclerosis	0.000993	0.00477	CcSEcCtD
Etravirine—Dermatitis bullous—Niacin—atherosclerosis	0.000992	0.00476	CcSEcCtD
Etravirine—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.000984	0.00473	CcSEcCtD
Etravirine—Breast disorder—Ezetimibe—atherosclerosis	0.000978	0.0047	CcSEcCtD
Etravirine—Gastritis—Ezetimibe—atherosclerosis	0.000958	0.0046	CcSEcCtD
Etravirine—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000949	0.00456	CcSEcCtD
Etravirine—Eosinophilia—Lovastatin—atherosclerosis	0.000945	0.00454	CcSEcCtD
Etravirine—Pancreatitis—Lovastatin—atherosclerosis	0.000935	0.00449	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00093	0.00447	CcSEcCtD
Etravirine—Eosinophilia—Ezetimibe—atherosclerosis	0.000926	0.00445	CcSEcCtD
Etravirine—Pancreatitis—Ezetimibe—atherosclerosis	0.000917	0.00441	CcSEcCtD
Etravirine—Gastritis—Simvastatin—atherosclerosis	0.000914	0.00439	CcSEcCtD
Etravirine—Hepatitis—Rosuvastatin—atherosclerosis	0.000901	0.00433	CcSEcCtD
Etravirine—Eosinophilia—Simvastatin—atherosclerosis	0.000883	0.00424	CcSEcCtD
Etravirine—Pancreatitis—Simvastatin—atherosclerosis	0.000875	0.0042	CcSEcCtD
Etravirine—Dry skin—Niacin—atherosclerosis	0.000869	0.00417	CcSEcCtD
Etravirine—Dry skin—Pravastatin—atherosclerosis	0.000856	0.00411	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000843	0.00405	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.00084	0.00404	CcSEcCtD
Etravirine—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000834	0.00401	CcSEcCtD
Etravirine—Abdominal distension—Niacin—atherosclerosis	0.000825	0.00396	CcSEcCtD
Etravirine—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.000818	0.00393	CcSEcCtD
Etravirine—Abdominal distension—Pravastatin—atherosclerosis	0.000812	0.0039	CcSEcCtD
Etravirine—Eosinophilia—Pravastatin—atherosclerosis	0.000799	0.00384	CcSEcCtD
Etravirine—Angina pectoris—Niacin—atherosclerosis	0.000798	0.00383	CcSEcCtD
Etravirine—Pancreatitis—Pravastatin—atherosclerosis	0.000791	0.0038	CcSEcCtD
Etravirine—Mental disorder—Rosuvastatin—atherosclerosis	0.000789	0.00379	CcSEcCtD
Etravirine—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000789	0.00379	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000789	0.00379	CcSEcCtD
Etravirine—Angina pectoris—Pravastatin—atherosclerosis	0.000786	0.00377	CcSEcCtD
Etravirine—Neuropathy peripheral—Simvastatin—atherosclerosis	0.00078	0.00375	CcSEcCtD
Etravirine—Flatulence—Rosuvastatin—atherosclerosis	0.000773	0.00371	CcSEcCtD
Etravirine—Hepatitis—Lovastatin—atherosclerosis	0.000764	0.00367	CcSEcCtD
Etravirine—Hepatitis—Ezetimibe—atherosclerosis	0.000749	0.0036	CcSEcCtD
Etravirine—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000736	0.00354	CcSEcCtD
Etravirine—Erythema multiforme—Lovastatin—atherosclerosis	0.000722	0.00347	CcSEcCtD
Etravirine—Angioedema—Rosuvastatin—atherosclerosis	0.000717	0.00344	CcSEcCtD
Etravirine—Hepatitis—Simvastatin—atherosclerosis	0.000714	0.00343	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000713	0.00343	CcSEcCtD
Etravirine—Stomatitis—Niacin—atherosclerosis	0.000712	0.00342	CcSEcCtD
Etravirine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000709	0.00341	CcSEcCtD
Etravirine—Erythema multiforme—Ezetimibe—atherosclerosis	0.000708	0.0034	CcSEcCtD
Etravirine—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000705	0.00339	CcSEcCtD
Etravirine—Myocardial infarction—Pravastatin—atherosclerosis	0.000705	0.00339	CcSEcCtD
Etravirine—Angiopathy—Ezetimibe—atherosclerosis	0.000679	0.00326	CcSEcCtD
Etravirine—Immune system disorder—Ezetimibe—atherosclerosis	0.000676	0.00325	CcSEcCtD
Etravirine—Erythema multiforme—Simvastatin—atherosclerosis	0.000675	0.00324	CcSEcCtD
Etravirine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000675	0.00324	CcSEcCtD
Etravirine—Mental disorder—Ezetimibe—atherosclerosis	0.000656	0.00315	CcSEcCtD
Etravirine—Hepatitis—Niacin—atherosclerosis	0.000656	0.00315	CcSEcCtD
Etravirine—Flatulence—Lovastatin—atherosclerosis	0.000655	0.00315	CcSEcCtD
Etravirine—Hypoaesthesia—Niacin—atherosclerosis	0.000653	0.00313	CcSEcCtD
Etravirine—Malnutrition—Ezetimibe—atherosclerosis	0.000652	0.00313	CcSEcCtD
Etravirine—Hepatitis—Pravastatin—atherosclerosis	0.000646	0.0031	CcSEcCtD
Etravirine—Confusional state—Rosuvastatin—atherosclerosis	0.000645	0.0031	CcSEcCtD
Etravirine—Hypoaesthesia—Pravastatin—atherosclerosis	0.000642	0.00309	CcSEcCtD
Etravirine—Flatulence—Ezetimibe—atherosclerosis	0.000642	0.00309	CcSEcCtD
Etravirine—Infection—Rosuvastatin—atherosclerosis	0.000636	0.00305	CcSEcCtD
Etravirine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000628	0.00302	CcSEcCtD
Etravirine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000627	0.00301	CcSEcCtD
Etravirine—Vision blurred—Lovastatin—atherosclerosis	0.000626	0.00301	CcSEcCtD
Etravirine—Mental disorder—Simvastatin—atherosclerosis	0.000626	0.00301	CcSEcCtD
Etravirine—Tremor—Lovastatin—atherosclerosis	0.000623	0.00299	CcSEcCtD
Etravirine—Ill-defined disorder—Lovastatin—atherosclerosis	0.000617	0.00296	CcSEcCtD
Etravirine—Eye disorder—Niacin—atherosclerosis	0.000613	0.00294	CcSEcCtD
Etravirine—Flatulence—Simvastatin—atherosclerosis	0.000613	0.00294	CcSEcCtD
Etravirine—Erythema multiforme—Pravastatin—atherosclerosis	0.000611	0.00293	CcSEcCtD
Etravirine—Angioedema—Lovastatin—atherosclerosis	0.000607	0.00292	CcSEcCtD
Etravirine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000605	0.00291	CcSEcCtD
Etravirine—Anaemia—Ezetimibe—atherosclerosis	0.000603	0.00289	CcSEcCtD
Etravirine—Malaise—Lovastatin—atherosclerosis	0.000599	0.00288	CcSEcCtD
Etravirine—Cardiac disorder—Pravastatin—atherosclerosis	0.000599	0.00288	CcSEcCtD
Etravirine—Vertigo—Lovastatin—atherosclerosis	0.000597	0.00287	CcSEcCtD
Etravirine—Angioedema—Ezetimibe—atherosclerosis	0.000596	0.00286	CcSEcCtD
Etravirine—Angiopathy—Niacin—atherosclerosis	0.000595	0.00286	CcSEcCtD
Etravirine—Malaise—Ezetimibe—atherosclerosis	0.000588	0.00282	CcSEcCtD
Etravirine—Vision blurred—Simvastatin—atherosclerosis	0.000586	0.00281	CcSEcCtD
Etravirine—Tremor—Simvastatin—atherosclerosis	0.000582	0.0028	CcSEcCtD
Etravirine—Insomnia—Rosuvastatin—atherosclerosis	0.000579	0.00278	CcSEcCtD
Etravirine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000577	0.00277	CcSEcCtD
Etravirine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000575	0.00276	CcSEcCtD
Etravirine—Anaemia—Simvastatin—atherosclerosis	0.000575	0.00276	CcSEcCtD
Etravirine—Malnutrition—Niacin—atherosclerosis	0.000571	0.00274	CcSEcCtD
Etravirine—Angioedema—Simvastatin—atherosclerosis	0.000568	0.00273	CcSEcCtD
Etravirine—Anxiety—Lovastatin—atherosclerosis	0.000564	0.00271	CcSEcCtD
Etravirine—Hypertension—Ezetimibe—atherosclerosis	0.000563	0.0027	CcSEcCtD
Etravirine—Flatulence—Niacin—atherosclerosis	0.000563	0.0027	CcSEcCtD
Etravirine—Malaise—Simvastatin—atherosclerosis	0.000561	0.00269	CcSEcCtD
Etravirine—Tension—Niacin—atherosclerosis	0.00056	0.00269	CcSEcCtD
Etravirine—Discomfort—Lovastatin—atherosclerosis	0.000559	0.00269	CcSEcCtD
Etravirine—Vertigo—Simvastatin—atherosclerosis	0.000559	0.00268	CcSEcCtD
Etravirine—Nervousness—Niacin—atherosclerosis	0.000554	0.00266	CcSEcCtD
Etravirine—Flatulence—Pravastatin—atherosclerosis	0.000554	0.00266	CcSEcCtD
Etravirine—Dry mouth—Lovastatin—atherosclerosis	0.000553	0.00266	CcSEcCtD
Etravirine—Tension—Pravastatin—atherosclerosis	0.000552	0.00265	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000551	0.00265	CcSEcCtD
Etravirine—Discomfort—Ezetimibe—atherosclerosis	0.000548	0.00263	CcSEcCtD
Etravirine—Pain—Rosuvastatin—atherosclerosis	0.000547	0.00263	CcSEcCtD
Etravirine—Constipation—Rosuvastatin—atherosclerosis	0.000547	0.00263	CcSEcCtD
Etravirine—Confusional state—Lovastatin—atherosclerosis	0.000547	0.00263	CcSEcCtD
Etravirine—Nervousness—Pravastatin—atherosclerosis	0.000546	0.00262	CcSEcCtD
Etravirine—Dry mouth—Ezetimibe—atherosclerosis	0.000543	0.00261	CcSEcCtD
Etravirine—Infection—Lovastatin—atherosclerosis	0.000539	0.00259	CcSEcCtD
Etravirine—Vision blurred—Niacin—atherosclerosis	0.000538	0.00258	CcSEcCtD
Etravirine—Confusional state—Ezetimibe—atherosclerosis	0.000537	0.00258	CcSEcCtD
Etravirine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000531	0.00255	CcSEcCtD
Etravirine—Vision blurred—Pravastatin—atherosclerosis	0.00053	0.00254	CcSEcCtD
Etravirine—Infection—Ezetimibe—atherosclerosis	0.000529	0.00254	CcSEcCtD
Etravirine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000527	0.00253	CcSEcCtD
Etravirine—Anxiety—Simvastatin—atherosclerosis	0.000527	0.00253	CcSEcCtD
Etravirine—Tremor—Pravastatin—atherosclerosis	0.000527	0.00253	CcSEcCtD
Etravirine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000523	0.00251	CcSEcCtD
Etravirine—Discomfort—Simvastatin—atherosclerosis	0.000523	0.00251	CcSEcCtD
Etravirine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000522	0.00251	CcSEcCtD
Etravirine—Angioedema—Niacin—atherosclerosis	0.000522	0.00251	CcSEcCtD
Etravirine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000522	0.00251	CcSEcCtD
Etravirine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000521	0.0025	CcSEcCtD
Etravirine—Anaemia—Pravastatin—atherosclerosis	0.00052	0.0025	CcSEcCtD
Etravirine—Anorexia—Lovastatin—atherosclerosis	0.000517	0.00248	CcSEcCtD
Etravirine—Skin disorder—Ezetimibe—atherosclerosis	0.000517	0.00248	CcSEcCtD
Etravirine—Angioedema—Pravastatin—atherosclerosis	0.000514	0.00247	CcSEcCtD
Etravirine—Vertigo—Niacin—atherosclerosis	0.000513	0.00246	CcSEcCtD
Etravirine—Syncope—Niacin—atherosclerosis	0.000512	0.00246	CcSEcCtD
Etravirine—Confusional state—Simvastatin—atherosclerosis	0.000512	0.00246	CcSEcCtD
Etravirine—Malaise—Pravastatin—atherosclerosis	0.000507	0.00243	CcSEcCtD
Etravirine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000506	0.00243	CcSEcCtD
Etravirine—Vertigo—Pravastatin—atherosclerosis	0.000505	0.00243	CcSEcCtD
Etravirine—Infection—Simvastatin—atherosclerosis	0.000504	0.00242	CcSEcCtD
Etravirine—Loss of consciousness—Niacin—atherosclerosis	0.000502	0.00241	CcSEcCtD
Etravirine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000497	0.00239	CcSEcCtD
Etravirine—Insomnia—Lovastatin—atherosclerosis	0.000491	0.00236	CcSEcCtD
Etravirine—Paraesthesia—Lovastatin—atherosclerosis	0.000487	0.00234	CcSEcCtD
Etravirine—Hypertension—Pravastatin—atherosclerosis	0.000485	0.00233	CcSEcCtD
Etravirine—Anorexia—Simvastatin—atherosclerosis	0.000484	0.00232	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000483	0.00232	CcSEcCtD
Etravirine—Insomnia—Ezetimibe—atherosclerosis	0.000481	0.00231	CcSEcCtD
Etravirine—Paraesthesia—Ezetimibe—atherosclerosis	0.000478	0.0023	CcSEcCtD
Etravirine—Anxiety—Pravastatin—atherosclerosis	0.000477	0.00229	CcSEcCtD
Etravirine—Dry mouth—Niacin—atherosclerosis	0.000475	0.00228	CcSEcCtD
Etravirine—Discomfort—Pravastatin—atherosclerosis	0.000473	0.00227	CcSEcCtD
Etravirine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000472	0.00227	CcSEcCtD
Etravirine—Decreased appetite—Lovastatin—atherosclerosis	0.000472	0.00227	CcSEcCtD
Etravirine—Fatigue—Lovastatin—atherosclerosis	0.000468	0.00225	CcSEcCtD
Etravirine—Pain—Lovastatin—atherosclerosis	0.000464	0.00223	CcSEcCtD
Etravirine—Constipation—Lovastatin—atherosclerosis	0.000464	0.00223	CcSEcCtD
Etravirine—Confusional state—Pravastatin—atherosclerosis	0.000463	0.00222	CcSEcCtD
Etravirine—Decreased appetite—Ezetimibe—atherosclerosis	0.000463	0.00222	CcSEcCtD
Etravirine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000459	0.00221	CcSEcCtD
Etravirine—Asthenia—Rosuvastatin—atherosclerosis	0.000459	0.00221	CcSEcCtD
Etravirine—Insomnia—Simvastatin—atherosclerosis	0.000459	0.0022	CcSEcCtD
Etravirine—Fatigue—Ezetimibe—atherosclerosis	0.000459	0.0022	CcSEcCtD
Etravirine—Shock—Niacin—atherosclerosis	0.000458	0.0022	CcSEcCtD
Etravirine—Infection—Pravastatin—atherosclerosis	0.000456	0.00219	CcSEcCtD
Etravirine—Paraesthesia—Simvastatin—atherosclerosis	0.000456	0.00219	CcSEcCtD
Etravirine—Pain—Ezetimibe—atherosclerosis	0.000455	0.00219	CcSEcCtD
Etravirine—Constipation—Ezetimibe—atherosclerosis	0.000455	0.00219	CcSEcCtD
Etravirine—Skin disorder—Niacin—atherosclerosis	0.000453	0.00217	CcSEcCtD
Etravirine—Hyperhidrosis—Niacin—atherosclerosis	0.00045	0.00216	CcSEcCtD
Etravirine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000449	0.00216	CcSEcCtD
Etravirine—Feeling abnormal—Lovastatin—atherosclerosis	0.000447	0.00215	CcSEcCtD
Etravirine—Anorexia—Niacin—atherosclerosis	0.000444	0.00213	CcSEcCtD
Etravirine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000444	0.00213	CcSEcCtD
Etravirine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000443	0.00213	CcSEcCtD
Etravirine—Decreased appetite—Simvastatin—atherosclerosis	0.000441	0.00212	CcSEcCtD
Etravirine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000438	0.00211	CcSEcCtD
Etravirine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000438	0.0021	CcSEcCtD
Etravirine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000438	0.0021	CcSEcCtD
Etravirine—Fatigue—Simvastatin—atherosclerosis	0.000437	0.0021	CcSEcCtD
Etravirine—Anorexia—Pravastatin—atherosclerosis	0.000437	0.0021	CcSEcCtD
Etravirine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000435	0.00209	CcSEcCtD
Etravirine—Constipation—Simvastatin—atherosclerosis	0.000434	0.00208	CcSEcCtD
Etravirine—Pain—Simvastatin—atherosclerosis	0.000434	0.00208	CcSEcCtD
Etravirine—Body temperature increased—Lovastatin—atherosclerosis	0.000429	0.00206	CcSEcCtD
Etravirine—Abdominal pain—Lovastatin—atherosclerosis	0.000429	0.00206	CcSEcCtD
Etravirine—Dizziness—Rosuvastatin—atherosclerosis	0.000423	0.00203	CcSEcCtD
Etravirine—Insomnia—Niacin—atherosclerosis	0.000421	0.00202	CcSEcCtD
Etravirine—Abdominal pain—Ezetimibe—atherosclerosis	0.000421	0.00202	CcSEcCtD
Etravirine—Body temperature increased—Ezetimibe—atherosclerosis	0.000421	0.00202	CcSEcCtD
Etravirine—Paraesthesia—Niacin—atherosclerosis	0.000418	0.00201	CcSEcCtD
Etravirine—Feeling abnormal—Simvastatin—atherosclerosis	0.000418	0.00201	CcSEcCtD
Etravirine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000415	0.00199	CcSEcCtD
Etravirine—Insomnia—Pravastatin—atherosclerosis	0.000415	0.00199	CcSEcCtD
Etravirine—Somnolence—Niacin—atherosclerosis	0.000414	0.00199	CcSEcCtD
Etravirine—Paraesthesia—Pravastatin—atherosclerosis	0.000412	0.00198	CcSEcCtD
Etravirine—Decreased appetite—Niacin—atherosclerosis	0.000405	0.00195	CcSEcCtD
Etravirine—Rash—Rosuvastatin—atherosclerosis	0.000404	0.00194	CcSEcCtD
Etravirine—Dermatitis—Rosuvastatin—atherosclerosis	0.000403	0.00194	CcSEcCtD
Etravirine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000402	0.00193	CcSEcCtD
Etravirine—Body temperature increased—Simvastatin—atherosclerosis	0.000401	0.00193	CcSEcCtD
Etravirine—Abdominal pain—Simvastatin—atherosclerosis	0.000401	0.00193	CcSEcCtD
Etravirine—Headache—Rosuvastatin—atherosclerosis	0.000401	0.00193	CcSEcCtD
Etravirine—Hypersensitivity—Lovastatin—atherosclerosis	0.0004	0.00192	CcSEcCtD
Etravirine—Decreased appetite—Pravastatin—atherosclerosis	0.000399	0.00192	CcSEcCtD
Etravirine—Pain—Niacin—atherosclerosis	0.000398	0.00191	CcSEcCtD
Etravirine—Fatigue—Pravastatin—atherosclerosis	0.000396	0.0019	CcSEcCtD
Etravirine—Pain—Pravastatin—atherosclerosis	0.000392	0.00188	CcSEcCtD
Etravirine—Constipation—Pravastatin—atherosclerosis	0.000392	0.00188	CcSEcCtD
Etravirine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000392	0.00188	CcSEcCtD
Etravirine—Asthenia—Lovastatin—atherosclerosis	0.000389	0.00187	CcSEcCtD
Etravirine—Asthenia—Ezetimibe—atherosclerosis	0.000382	0.00183	CcSEcCtD
Etravirine—Gastrointestinal pain—Niacin—atherosclerosis	0.000381	0.00183	CcSEcCtD
Etravirine—Nausea—Rosuvastatin—atherosclerosis	0.00038	0.00183	CcSEcCtD
Etravirine—Feeling abnormal—Pravastatin—atherosclerosis	0.000378	0.00182	CcSEcCtD
Etravirine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000375	0.0018	CcSEcCtD
Etravirine—Hypersensitivity—Simvastatin—atherosclerosis	0.000374	0.0018	CcSEcCtD
Etravirine—Diarrhoea—Lovastatin—atherosclerosis	0.000371	0.00178	CcSEcCtD
Etravirine—Abdominal pain—Niacin—atherosclerosis	0.000368	0.00177	CcSEcCtD
Etravirine—Body temperature increased—Niacin—atherosclerosis	0.000368	0.00177	CcSEcCtD
Etravirine—Asthenia—Simvastatin—atherosclerosis	0.000364	0.00175	CcSEcCtD
Etravirine—Diarrhoea—Ezetimibe—atherosclerosis	0.000364	0.00175	CcSEcCtD
Etravirine—Abdominal pain—Pravastatin—atherosclerosis	0.000363	0.00174	CcSEcCtD
Etravirine—Body temperature increased—Pravastatin—atherosclerosis	0.000363	0.00174	CcSEcCtD
Etravirine—Dizziness—Lovastatin—atherosclerosis	0.000359	0.00172	CcSEcCtD
Etravirine—Dizziness—Ezetimibe—atherosclerosis	0.000352	0.00169	CcSEcCtD
Etravirine—Diarrhoea—Simvastatin—atherosclerosis	0.000347	0.00167	CcSEcCtD
Etravirine—Vomiting—Lovastatin—atherosclerosis	0.000345	0.00166	CcSEcCtD
Etravirine—Hypersensitivity—Niacin—atherosclerosis	0.000343	0.00165	CcSEcCtD
Etravirine—Rash—Lovastatin—atherosclerosis	0.000342	0.00164	CcSEcCtD
Etravirine—Dermatitis—Lovastatin—atherosclerosis	0.000342	0.00164	CcSEcCtD
Etravirine—Headache—Lovastatin—atherosclerosis	0.00034	0.00163	CcSEcCtD
Etravirine—Vomiting—Ezetimibe—atherosclerosis	0.000338	0.00163	CcSEcCtD
Etravirine—Hypersensitivity—Pravastatin—atherosclerosis	0.000338	0.00162	CcSEcCtD
Etravirine—Dizziness—Simvastatin—atherosclerosis	0.000336	0.00161	CcSEcCtD
Etravirine—Rash—Ezetimibe—atherosclerosis	0.000335	0.00161	CcSEcCtD
Etravirine—Dermatitis—Ezetimibe—atherosclerosis	0.000335	0.00161	CcSEcCtD
Etravirine—Asthenia—Niacin—atherosclerosis	0.000334	0.00161	CcSEcCtD
Etravirine—Headache—Ezetimibe—atherosclerosis	0.000333	0.0016	CcSEcCtD
Etravirine—Asthenia—Pravastatin—atherosclerosis	0.000329	0.00158	CcSEcCtD
Etravirine—Vomiting—Simvastatin—atherosclerosis	0.000323	0.00155	CcSEcCtD
Etravirine—Nausea—Lovastatin—atherosclerosis	0.000322	0.00155	CcSEcCtD
Etravirine—Rash—Simvastatin—atherosclerosis	0.00032	0.00154	CcSEcCtD
Etravirine—Dermatitis—Simvastatin—atherosclerosis	0.00032	0.00154	CcSEcCtD
Etravirine—Diarrhoea—Niacin—atherosclerosis	0.000319	0.00153	CcSEcCtD
Etravirine—Headache—Simvastatin—atherosclerosis	0.000318	0.00153	CcSEcCtD
Etravirine—Nausea—Ezetimibe—atherosclerosis	0.000316	0.00152	CcSEcCtD
Etravirine—Diarrhoea—Pravastatin—atherosclerosis	0.000314	0.00151	CcSEcCtD
Etravirine—Dizziness—Niacin—atherosclerosis	0.000308	0.00148	CcSEcCtD
Etravirine—Dizziness—Pravastatin—atherosclerosis	0.000303	0.00146	CcSEcCtD
Etravirine—Nausea—Simvastatin—atherosclerosis	0.000301	0.00145	CcSEcCtD
Etravirine—Vomiting—Niacin—atherosclerosis	0.000296	0.00142	CcSEcCtD
Etravirine—Rash—Niacin—atherosclerosis	0.000294	0.00141	CcSEcCtD
Etravirine—Dermatitis—Niacin—atherosclerosis	0.000293	0.00141	CcSEcCtD
Etravirine—Headache—Niacin—atherosclerosis	0.000292	0.0014	CcSEcCtD
Etravirine—Vomiting—Pravastatin—atherosclerosis	0.000292	0.0014	CcSEcCtD
Etravirine—Rash—Pravastatin—atherosclerosis	0.000289	0.00139	CcSEcCtD
Etravirine—Dermatitis—Pravastatin—atherosclerosis	0.000289	0.00139	CcSEcCtD
Etravirine—Headache—Pravastatin—atherosclerosis	0.000287	0.00138	CcSEcCtD
Etravirine—Nausea—Niacin—atherosclerosis	0.000277	0.00133	CcSEcCtD
Etravirine—Nausea—Pravastatin—atherosclerosis	0.000272	0.00131	CcSEcCtD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—APOA5—atherosclerosis	4.71e-05	0.000414	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PLTP—atherosclerosis	4.62e-05	0.000406	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G1B—atherosclerosis	4.53e-05	0.000398	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PLTP—atherosclerosis	4.51e-05	0.000396	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LDLRAP1—atherosclerosis	4.48e-05	0.000394	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—atherosclerosis	4.38e-05	0.000385	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	4.28e-05	0.000376	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	4.25e-05	0.000374	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—atherosclerosis	4.23e-05	0.000372	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	4.23e-05	0.000372	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PLTP—atherosclerosis	4.21e-05	0.00037	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTM1—atherosclerosis	4.17e-05	0.000366	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	4.13e-05	0.000363	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—AKT1—atherosclerosis	4.12e-05	0.000362	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—GSTM1—atherosclerosis	4.11e-05	0.000361	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ABCG8—atherosclerosis	4.01e-05	0.000352	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—LTA4H—atherosclerosis	4.01e-05	0.000352	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	3.96e-05	0.000347	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—LTA4H—atherosclerosis	3.91e-05	0.000344	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ABCG8—atherosclerosis	3.91e-05	0.000344	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	3.9e-05	0.000343	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	3.88e-05	0.000341	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	3.86e-05	0.000339	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—CETP—atherosclerosis	3.83e-05	0.000337	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	3.77e-05	0.000331	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	3.74e-05	0.000328	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ABCG8—atherosclerosis	3.65e-05	0.000321	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LTA4H—atherosclerosis	3.65e-05	0.000321	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	3.61e-05	0.000317	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	3.51e-05	0.000308	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	3.41e-05	0.000299	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	3.38e-05	0.000297	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	3.33e-05	0.000292	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ABCG1—atherosclerosis	3.17e-05	0.000278	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ABCG1—atherosclerosis	3.09e-05	0.000272	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	3.04e-05	0.000267	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	3.04e-05	0.000267	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	2.99e-05	0.000263	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—LCAT—atherosclerosis	2.98e-05	0.000262	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—FABP4—atherosclerosis	2.98e-05	0.000262	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	2.96e-05	0.00026	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOA4—atherosclerosis	2.92e-05	0.000257	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—FABP4—atherosclerosis	2.91e-05	0.000255	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—LCAT—atherosclerosis	2.91e-05	0.000255	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ABCG1—atherosclerosis	2.89e-05	0.000254	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	2.87e-05	0.000252	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP7A1—atherosclerosis	2.87e-05	0.000252	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOA4—atherosclerosis	2.85e-05	0.000251	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP7A1—atherosclerosis	2.8e-05	0.000246	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PLTP—atherosclerosis	2.78e-05	0.000244	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	2.76e-05	0.000243	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	2.74e-05	0.00024	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—FABP4—atherosclerosis	2.71e-05	0.000239	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LCAT—atherosclerosis	2.71e-05	0.000239	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOA4—atherosclerosis	2.66e-05	0.000234	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP27A1—atherosclerosis	2.65e-05	0.000233	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	2.65e-05	0.000233	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP7A1—atherosclerosis	2.62e-05	0.00023	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	2.61e-05	0.00023	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.61e-05	0.00023	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP27A1—atherosclerosis	2.59e-05	0.000228	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.55e-05	0.000224	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—AKT1—atherosclerosis	2.55e-05	0.000224	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	2.54e-05	0.000223	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	2.54e-05	0.000223	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOA2—atherosclerosis	2.52e-05	0.000221	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PLA2G2A—atherosclerosis	2.52e-05	0.000221	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ALOX5AP—atherosclerosis	2.52e-05	0.000221	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ALOX15—atherosclerosis	2.52e-05	0.000221	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	2.49e-05	0.000219	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ABCG5—atherosclerosis	2.49e-05	0.000218	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.48e-05	0.000218	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ALOX15—atherosclerosis	2.46e-05	0.000216	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PLA2G2A—atherosclerosis	2.46e-05	0.000216	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ALOX5AP—atherosclerosis	2.46e-05	0.000216	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOA2—atherosclerosis	2.46e-05	0.000216	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ABCG5—atherosclerosis	2.43e-05	0.000213	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP27A1—atherosclerosis	2.42e-05	0.000213	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LTA4H—atherosclerosis	2.41e-05	0.000212	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ABCG8—atherosclerosis	2.41e-05	0.000212	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—LPA—atherosclerosis	2.4e-05	0.000211	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	2.38e-05	0.000209	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	2.37e-05	0.000208	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—LPA—atherosclerosis	2.34e-05	0.000206	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—BGN—atherosclerosis	2.32e-05	0.000204	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	2.32e-05	0.000204	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.31e-05	0.000203	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOA5—atherosclerosis	2.3e-05	0.000202	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ALOX15—atherosclerosis	2.29e-05	0.000202	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PLA2G2A—atherosclerosis	2.29e-05	0.000202	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ALOX5AP—atherosclerosis	2.29e-05	0.000202	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOA2—atherosclerosis	2.29e-05	0.000202	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—BGN—atherosclerosis	2.27e-05	0.000199	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ABCG5—atherosclerosis	2.27e-05	0.000199	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	2.26e-05	0.000199	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOA5—atherosclerosis	2.25e-05	0.000197	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.24e-05	0.000196	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PLA2G1B—atherosclerosis	2.21e-05	0.000195	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.19e-05	0.000192	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LPA—atherosclerosis	2.19e-05	0.000192	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.17e-05	0.000191	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.16e-05	0.00019	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PLA2G1B—atherosclerosis	2.16e-05	0.00019	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	2.14e-05	0.000188	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ALOX5—atherosclerosis	2.14e-05	0.000188	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—BGN—atherosclerosis	2.12e-05	0.000186	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.1e-05	0.000185	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOA5—atherosclerosis	2.1e-05	0.000184	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ALOX5—atherosclerosis	2.09e-05	0.000183	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.04e-05	0.000179	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	2.02e-05	0.000177	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	2.01e-05	0.000177	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2e-05	0.000175	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.98e-05	0.000174	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.98e-05	0.000174	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.97e-05	0.000173	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ALOX5—atherosclerosis	1.95e-05	0.000171	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NAMPT—atherosclerosis	1.92e-05	0.000169	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.91e-05	0.000168	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—LIPC—atherosclerosis	1.91e-05	0.000167	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.9e-05	0.000167	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOC3—atherosclerosis	1.89e-05	0.000166	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—LDLR—atherosclerosis	1.88e-05	0.000165	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NAMPT—atherosclerosis	1.87e-05	0.000165	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—LIPC—atherosclerosis	1.86e-05	0.000163	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOC3—atherosclerosis	1.85e-05	0.000162	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CETP—atherosclerosis	1.84e-05	0.000162	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—LDLR—atherosclerosis	1.84e-05	0.000161	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.8e-05	0.000158	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CETP—atherosclerosis	1.8e-05	0.000158	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—FABP4—atherosclerosis	1.79e-05	0.000157	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LCAT—atherosclerosis	1.79e-05	0.000157	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.76e-05	0.000155	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—SCARB1—atherosclerosis	1.76e-05	0.000155	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOA4—atherosclerosis	1.76e-05	0.000154	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NAMPT—atherosclerosis	1.75e-05	0.000154	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.74e-05	0.000153	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LIPC—atherosclerosis	1.74e-05	0.000153	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOC3—atherosclerosis	1.73e-05	0.000152	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.73e-05	0.000152	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—SCARB1—atherosclerosis	1.72e-05	0.000151	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LDLR—atherosclerosis	1.72e-05	0.000151	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.72e-05	0.000151	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CETP—atherosclerosis	1.68e-05	0.000147	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—HMGCR—atherosclerosis	1.66e-05	0.000146	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—HMGCR—atherosclerosis	1.62e-05	0.000143	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—SCARB1—atherosclerosis	1.61e-05	0.000141	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.6e-05	0.00014	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.59e-05	0.00014	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.56e-05	0.000137	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—HMGCR—atherosclerosis	1.52e-05	0.000133	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.51e-05	0.000133	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.51e-05	0.000133	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.51e-05	0.000133	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOA2—atherosclerosis	1.51e-05	0.000133	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.5e-05	0.000132	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.49e-05	0.000131	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ABCA1—atherosclerosis	1.48e-05	0.00013	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ABCA1—atherosclerosis	1.45e-05	0.000127	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LPA—atherosclerosis	1.44e-05	0.000127	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—BGN—atherosclerosis	1.4e-05	0.000123	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOA5—atherosclerosis	1.38e-05	0.000122	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.37e-05	0.00012	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ABCA1—atherosclerosis	1.35e-05	0.000119	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.33e-05	0.000117	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.29e-05	0.000113	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—HMOX1—atherosclerosis	1.27e-05	0.000112	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—HMOX1—atherosclerosis	1.24e-05	0.000109	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOB—atherosclerosis	1.22e-05	0.000107	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOB—atherosclerosis	1.19e-05	0.000104	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTM1—atherosclerosis	1.19e-05	0.000104	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—LPL—atherosclerosis	1.16e-05	0.000102	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.16e-05	0.000102	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTM1—atherosclerosis	1.16e-05	0.000102	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.15e-05	0.000101	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LIPC—atherosclerosis	1.15e-05	0.000101	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOC3—atherosclerosis	1.14e-05	0.0001	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—LPL—atherosclerosis	1.14e-05	9.98e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GPX1—atherosclerosis	1.14e-05	9.97e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LDLR—atherosclerosis	1.13e-05	9.95e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOB—atherosclerosis	1.11e-05	9.76e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GPX1—atherosclerosis	1.11e-05	9.73e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CETP—atherosclerosis	1.11e-05	9.72e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CD36—atherosclerosis	1.11e-05	9.71e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.08e-05	9.5e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CD36—atherosclerosis	1.08e-05	9.48e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—LPL—atherosclerosis	1.06e-05	9.32e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.06e-05	9.31e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—MTHFR—atherosclerosis	1.05e-05	9.2e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GPX1—atherosclerosis	1.04e-05	9.09e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PPARA—atherosclerosis	1.03e-05	9.03e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—MTHFR—atherosclerosis	1.02e-05	8.98e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CD36—atherosclerosis	1.01e-05	8.86e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PPARA—atherosclerosis	1e-05	8.81e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—HMGCR—atherosclerosis	1e-05	8.79e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—AGT—atherosclerosis	9.95e-06	8.74e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOE—atherosclerosis	9.75e-06	8.57e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—AGT—atherosclerosis	9.72e-06	8.53e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CAV1—atherosclerosis	9.66e-06	8.49e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOA1—atherosclerosis	9.64e-06	8.47e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—MTHFR—atherosclerosis	9.55e-06	8.39e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOE—atherosclerosis	9.52e-06	8.36e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CAV1—atherosclerosis	9.43e-06	8.29e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOA1—atherosclerosis	9.41e-06	8.27e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PPARA—atherosclerosis	9.37e-06	8.23e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—AGT—atherosclerosis	9.08e-06	7.97e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ABCA1—atherosclerosis	8.92e-06	7.83e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOE—atherosclerosis	8.89e-06	7.81e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CAV1—atherosclerosis	8.81e-06	7.74e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	8.8e-06	7.73e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOA1—atherosclerosis	8.79e-06	7.72e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PIK3CG—atherosclerosis	8.59e-06	7.55e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PPARG—atherosclerosis	8.49e-06	7.46e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—INS—atherosclerosis	8.33e-06	7.32e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PPARG—atherosclerosis	8.29e-06	7.28e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—INS—atherosclerosis	8.13e-06	7.14e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	8.03e-06	7.05e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PPARG—atherosclerosis	7.75e-06	6.8e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—HMOX1—atherosclerosis	7.65e-06	6.72e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ALB—atherosclerosis	7.64e-06	6.71e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—INS—atherosclerosis	7.6e-06	6.67e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ALB—atherosclerosis	7.46e-06	6.55e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOB—atherosclerosis	7.33e-06	6.44e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NOS3—atherosclerosis	7.31e-06	6.42e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NOS3—atherosclerosis	7.13e-06	6.27e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTM1—atherosclerosis	7.13e-06	6.26e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—LPL—atherosclerosis	7e-06	6.15e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ALB—atherosclerosis	6.96e-06	6.12e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GPX1—atherosclerosis	6.83e-06	6e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PTGS2—atherosclerosis	6.68e-06	5.87e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NOS3—atherosclerosis	6.66e-06	5.85e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CD36—atherosclerosis	6.65e-06	5.84e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PTGS2—atherosclerosis	6.52e-06	5.73e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—MTHFR—atherosclerosis	6.3e-06	5.53e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PPARA—atherosclerosis	6.18e-06	5.43e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PTGS2—atherosclerosis	6.09e-06	5.35e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—AGT—atherosclerosis	5.99e-06	5.26e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOE—atherosclerosis	5.86e-06	5.15e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CAV1—atherosclerosis	5.81e-06	5.1e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOA1—atherosclerosis	5.8e-06	5.09e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.29e-06	4.65e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PPARG—atherosclerosis	5.11e-06	4.49e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—INS—atherosclerosis	5.01e-06	4.4e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ALB—atherosclerosis	4.59e-06	4.04e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NOS3—atherosclerosis	4.39e-06	3.86e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PTGS2—atherosclerosis	4.02e-06	3.53e-05	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—AKT1—atherosclerosis	3.36e-06	2.95e-05	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—AKT1—atherosclerosis	3.28e-06	2.88e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—AKT1—atherosclerosis	3.06e-06	2.69e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—AKT1—atherosclerosis	2.02e-06	1.77e-05	CbGpPWpGaD
